Cambrex exits drug product
CDMO Cambrex has sold its Drug Product business unit to Noramco. Terms were not disclosed. The business comprises product development, clinical and commercial manufacturing and packaging from facilities in Mirabel, Québec, and Whippany, New Jersey.
CEO Thomas Loewald described this as “the result of a strategic decision to focus on core areas of growth and investment”. The company will henceforth prioritise its drug substance and analytical testing businesses, which are based across 13 sites worldwide, including the recently acquired Snapdragon Chemistry and Q1 Scientific.